Genome Publications
https://doi.org/10.61096/978-81-981372-2-7_18

Chapter 18

Pharmacogenomics and Precision Dosing

Ramya Adivenkataraman
Department of Pharmacy Practice, JSS College of Pharmacy, JSS Academy of Higher Education & Research, Ooty, Nilgiris, Tamil Nadu, India
Kannan Raman
Department of Pharmacology, St. John's College of Pharmaceutical Sciences & Research, Kattappana, Idukki 685515, Kerela, India.
Kavin Kumar MC
Department of Pharmaceutical Chemistry, Vellalar College of Pharmacy, Erode, Tamil Nadu, India

Abstract: Pharmacogenomics (PGx) represents a transformative paradigm in modern therapeutics, shifting drug development and clinical practice from empirical, population-based prescribing toward individualized, genotype-guided treatment. Advances in genomic sequencing, computational biology, and clinical decision support systems have enabled the identification of actionable pharmacogenetic variants that influence pharmacokinetics and pharmacodynamics. Key genes such as CYP2D6, CYP2C19, TPMT, UGT1A1, and VKORC1 have been implicated in variability of drug metabolism and therapeutic response, while human leukocyte antigen alleles (HLA-B57:01, HLA-B15:02) play pivotal roles in predicting severe hypersensitivity reactions. Integration of pharmacogenomic testing into electronic health records, alongside pre-emptive and pharmacist-led models of care, has facilitated clinical uptake. Furthermore, precision dosing tools, polygenic risk scores, and AI-assisted prediction models are enhancing the utility of pharmacogenomics beyond single-gene analysis. Despite promising advances, challenges remain in cost-effectiveness, equitable access, regulatory harmonization, and ethical concerns around data privacy and genetic discrimination. This chapter provides a comprehensive review of pharmacogenomics and precision dosing, emphasizing key pharmacogenes, clinical implementation frameworks, therapeutic area-specific applications, and the evolving role of computational models and multi-omic integration. Future perspectives highlight genome editing, pharmacoepigenomics, and proteogenomics as avenues to further refine individualized therapy and improve patient outcomes.

Keywords: Pharmacogenomics, Precision dosing, Pharmacogenetic variants, Personalized medicine, Genetic testing.

Citation: Ramya Adivenkataraman, Kannan Raman, Kavin Kumar MC. Pharmacogenomics and Precision Dosing. *Modern Therapeutic Pharmacology: Precision Therapeutics Across Organ Systems*. Genome Publications. 2025; Pp190-200. https://doi.org/10.61096/978-81-981372-2-7_18

18.0 INTRODUCTION

The field of pharmacogenomics has emerged as a cornerstone of precision medicine, fundamentally challenging the long-standing "one-size-fits-all" approach to drug prescribing. Traditionally, therapeutic regimens have been derived from clinical trial data that reflect population averages, often disregarding the substantial interindividual variability in drug efficacy and safety. Genetic diversity is a critical determinant of these differences, encompassing single nucleotide polymorphisms (SNPs), gene duplications or deletions, and copy number variations that influence pharmacokinetic processes such as absorption, distribution, metabolism, and excretion (ADME), as well as pharmacodynamic targets such as receptors and transporters [1]. These genetic determinants can result in suboptimal drug responses, ranging from therapeutic failure to life-threatening adverse reactions.

Over the past two decades, genome-wide association studies (GWAS) and advances in next-generation sequencing technologies have expanded our understanding of how genetic variability translates into clinical phenotypes. The clinical application of this knowledge has been exemplified in the pharmacogenomics-guided use of warfarin, clopidogrel, thiopurines, and antidepressants. The integration of pharmacogenomic data into drug labeling by regulatory agencies such as the United States Food and Drug Administration (FDA) underscores the translational value of these insights [2].

The evolution of pharmacogenomics is not merely scientific but also economic and ethical. Although the cost of sequencing has dropped dramatically, the affordability and accessibility of pharmacogenomic testing remain uneven across healthcare systems. Moreover, the equitable distribution of benefits across diverse populations is challenged by underrepresentation of certain ethnic groups in genetic studies [3]. In parallel, clinical decision support systems integrated into electronic health records (EHRs) are beginning to operationalize pharmacogenomic knowledge at the point of care, enabling clinicians to tailor therapy in real time.

Therefore, pharmacogenomics represents a paradigm shift with significant implications for therapeutics, drug development, and healthcare policy. The following sections will delve into key pharmacogenes and actionable variants, clinical implementation strategies, and therapeutic area-specific applications, before discussing precision dosing tools, polygenic models, ethical dilemmas, and future perspectives.

18.1 Key Pharmacogenes and Actionable Variants

The clinical translation of pharmacogenomics relies on well-characterized gene–drug pairs supported by strong evidence of clinical utility. Among the most extensively studied are the cytochrome P450 (CYP) enzymes, thiopurine methyltransferase (TPMT), uridine diphosphate glucuronosyltransferase (UGT1A1), and vitamin K epoxide reductase complex 1 (VKORC1). Variants in these genes significantly influence drug metabolism and therapeutic outcomes [4].

CYP2D6 polymorphisms illustrate the complexity of pharmacogenetic variability. Over 100 known alleles contribute to a spectrum of metabolizer phenotypes: poor, intermediate, normal, and ultra-rapid metabolizers. Clinically, CYP2D6 status affects metabolism of opioids such as codeine and tramadol, where ultra-rapid metabolizers risk opioid toxicity due to excessive morphine formation, while poor metabolizers may experience inadequate analgesia [5]. Similarly, CYP2C19 variants alter the activation of clopidogrel, with loss-of-function alleles (CYP2C19 *2, *3) reducing antiplatelet efficacy and increasing cardiovascular risk.

Beyond CYP enzymes, TPMT polymorphisms play a decisive role in thiopurine therapy, where reduced enzyme activity increases risk of life-threatening myelosuppression. UGT1A1 variants,

particularly UGT1A1 28, reduce glucuronidation of irinotecan, predisposing patients to severe neutropenia and diarrhea [6]. Meanwhile, VKORC1 polymorphisms, together with CYP2C9 variants, underpin variability in warfarin sensitivity, necessitating genotype-guided dosing algorithms.

Immunogenetics provides another domain of actionable pharmacogenomics. The HLA-B57:01 allele predicts hypersensitivity to abacavir, leading to its inclusion as a mandatory pre-treatment genetic screen in antiretroviral therapy. Similarly, HLA-B15:02 strongly predicts carbamazepine-induced Stevens–Johnson syndrome and toxic epidermal necrolysis in Asian populations [7]. These examples highlight the importance of tailoring pharmacogenomic implementation to population-specific allele frequencies.

In recent years, attention has expanded to opioid receptor genetics. Polymorphisms in the μ-opioid receptor gene (OPRM1) have been linked to differences in opioid efficacy, tolerance, and dependence. Likewise, variants in transporters such as SLCO1B1 affect statin pharmacokinetics and risk of myopathy [8]. Collectively, these pharmacogenes underscore the potential for improving therapeutic safety and efficacy through genetic insights.

18.2 Clinical Implementation of PGx

The translation of pharmacogenomics into clinical practice has been facilitated by guideline development, integration into clinical workflows, and the emergence of pharmacist-led services. The Clinical Pharmacogenetics Implementation Consortium (CPIC) provides peer-reviewed, evidence-based guidelines that translate genetic test results into actionable prescribing recommendations. Similarly, PharmGKB serves as a curated knowledgebase for gene–drug associations, supporting both research and clinical decision-making [9].

Implementation strategies can be broadly divided into reactive and pre-emptive models. Reactive testing occurs at the time of prescribing a specific drug, guided by immediate clinical need. Pre-emptive testing involves genotyping panels or whole exome sequencing performed before therapy initiation, with results stored in EHRs for future use. While pre-emptive approaches enhance long-term cost-effectiveness and prevent adverse reactions across multiple drugs, they require upfront investment and robust informatics infrastructure [10].

Electronic health record integration is critical for successful adoption. Clinical decision support systems (CDSS) embedded within EHRs can provide real-time prescribing alerts based on a patient's genotype, reducing the burden on clinicians. Studies have shown that CDSS integration increases adherence to pharmacogenomic guidelines and reduces adverse events [11]. Pharmacists play a pivotal role in this ecosystem, often leading pharmacogenomic services by interpreting test results, counseling patients, and collaborating with prescribers.

Despite these advances, barriers to widespread implementation remain. Challenges include variable insurance coverage, inconsistent reimbursement models, and limited availability of trained personnel in many healthcare systems. Moreover, implementation must address disparities in genomic data representation, as allele frequencies differ substantially across populations, underscoring the need for diversity in genetic research [12].

As clinical adoption progresses, lessons from early implementation programs such as the U.S. IGNITE (Implementing Genomics in Practice) Network and Europe's U-PGx project demonstrate the feasibility of scaling pharmacogenomic testing across healthcare systems. These initiatives emphasize the value of collaborative, multi-institutional efforts to establish sustainable, standardized frameworks for pharmacogenomics in routine care.

18.3 PGx in Key Therapeutic Areas

Pharmacogenomics has found its most immediate and impactful applications in specific therapeutic domains, where variability in drug response has historically posed clinical challenges. In cardiology, oncology, psychiatry, and pain medicine, genotype-guided prescribing has reshaped clinical decision-making and patient outcomes.

In cardiology, warfarin dosing exemplifies the clinical relevance of pharmacogenomics. Traditional dosing algorithms based on age, body weight, and clinical history often fail to capture interindividual variability in response. Variants in VKORC1 and CYP2C9 substantially influence sensitivity and clearance, making genotype-guided algorithms more effective at predicting therapeutic international normalized ratio (INR) levels and reducing adverse bleeding events [13]. Similarly, clopidogrel response is highly dependent on CYP2C19 activity. Loss-of-function alleles compromise prodrug activation, increasing thrombotic risk following percutaneous coronary intervention. Consequently, both FDA and CPIC recommend alternative antiplatelet agents, such as prasugrel or ticagrelor, in poor metabolizers [14].

Oncology has also embraced pharmacogenomic testing, particularly for thiopurines and irinotecan. TPMT and NUDT15 polymorphisms significantly alter thiopurine metabolism, and dose reductions based on genotype prevent severe myelosuppression. For irinotecan, UGT1A1 28 homozygotes experience decreased glucuronidation, predisposing them to neutropenia and diarrhea; pre-emptive testing improves therapeutic safety [15]. Tumor genomics adds another dimension, as genetic variants within tumor tissue guide targeted therapies, distinct from germline pharmacogenomics. The advent of liquid biopsies provides a non-invasive route for assessing tumor mutations, enhancing real-time treatment adaptation [16].

In psychiatry, selective serotonin reuptake inhibitors (SSRIs) and tricyclic antidepressants show marked variability in efficacy and tolerability due to CYP2C19 and CYP2D6 polymorphisms. Integration of PGx testing into psychiatric practice reduces trial-and-error prescribing, shortens time to therapeutic response, and lowers risk of adverse effects [17]. Similarly, pain management strategies are influenced by both CYP2D6 activity and OPRM1 variants, shaping opioid efficacy, toxicity, and dependence potential [18].

These case studies illustrate how pharmacogenomics, when translated into clinical practice, optimizes therapeutic benefit while minimizing harm. However, implementation requires careful balancing of clinical utility, accessibility, and cost-effectiveness.

18.4 Companion Diagnostics and Labeling Requirements

Companion diagnostics (CDx) are laboratory tests developed to identify patients most likely to benefit from a specific drug, or conversely, those at greatest risk of harm. Regulatory bodies, particularly the FDA, have integrated pharmacogenomic biomarkers into drug labeling to ensure safer prescribing. Drugs such as abacavir (HLA-B57:01 screening), trastuzumab (HER2 testing), and cetuximab (KRAS mutation testing) are prime examples of CDx-driven therapies [19].

The FDA's Table of Pharmacogenomic Biomarkers in Drug Labeling lists over 400 entries, encompassing both germline and somatic biomarkers [20]. These labels range from mandatory genetic testing requirements (e.g., abacavir) to informational guidance. Post-marketing surveillance further evaluates clinical validity and utility, ensuring ongoing safety. Internationally, the European Medicines Agency (EMA) and Japanese regulatory bodies have established parallel frameworks, though harmonization of guidelines remains a challenge.

Companion diagnostics extend beyond oncology, with growing application in cardiology and psychiatry. They represent a crucial interface between laboratory genomics and therapeutic practice, bridging drug development, regulatory science, and clinical implementation.

Table 18.1: Examples of FDA-Approved Pharmacogenomic Biomarkers in Drug Labeling

Drug	Gene/Biomarker	Clinical Relevance	Testing Requirement
Abacavir	HLA-B57:01	Hypersensitivity risk	Mandatory
Clopidogrel	CYP2C19	Poor antiplatelet response in LOF allele carriers	Recommended
Irinotecan	UGT1A1 28	Risk of severe neutropenia and diarrhea	Informational
Warfarin	VKORC1, CYP2C9	Variability in anticoagulant sensitivity	Informational (algorithm use)
Carbamazepine	HLA-B15:02	Stevens–Johnson syndrome/TEN risk in Asians	Mandatory in high-risk groups

18.5 Polygenic Risk Scores and Multi-Gene Panels

While single-gene analysis remains the dominant framework, the growing recognition of polygenic contributions to drug response has fueled development of polygenic risk scores (PRS) and multi-gene panels. Unlike monogenic models, PRS aggregate the effect of multiple common variants, providing a more nuanced prediction of drug efficacy and toxicity. This approach has shown promise in predicting statin-induced myopathy, warfarin dosing, and antidepressant response [21].

Multi-gene PGx panels, often including dozens of pharmacogenes, are increasingly used in pre-emptive testing models. They offer efficiency by capturing a wide spectrum of drug–gene interactions, reducing the need for repeated testing. However, interpretation is complex, requiring advanced computational algorithms and careful clinical validation [22]. Population-specific considerations are critical in PRS development. Many existing risk scores are biased toward European populations, limiting transferability to diverse ethnic groups. Initiatives such as the All of Us Research Program in the United States and GenomeAsia 100K are working to address this imbalance by generating more representative datasets [23].

Artificial intelligence and machine learning approaches are further enhancing PRS by integrating multi-omic layers such as transcriptomics, proteomics, and epigenomics. These models hold the potential to capture complex, nonlinear interactions between genetic and environmental factors, paving the way for highly individualized predictions [24]. Despite their promise, polygenic models face hurdles in clinical adoption. Issues of standardization, interpretability, and reimbursement remain unresolved. Nevertheless, their evolution represents the next frontier in pharmacogenomics, expanding beyond the confines of single-gene analysis.

Table 18.2: Emerging Precision Dosing Tools and Algorithms

Tool/Platform	Application	Integration
Warfarin Dosing Algorithms	CYP2C9 and VKORC1-based models	EHR decision support
Thiopurine Dosing Apps	TPMT and NUDT15 dose calculators	Mobile and clinical pharmacy services
Bayesian TDM Software	Oncology, infectious disease drugs	Laboratory integration

AI-Guided CDSS	Multi-omic precision dosing	Predictive analytics
Blockchain Data Platforms	Secure genomic data exchange	Patient–provider networks



Figure 1: Pharmacogenomic Applications in Major Therapeutic Areas

18.6 Drug Transporters and Non-CYP Pathways

Although cytochrome P450 enzymes dominate pharmacogenomic discourse, drug transporters and non-CYP metabolic pathways exert equally significant influence on drug disposition and therapeutic outcomes. The solute carrier organic anion transporter family member SLCO1B1 exemplifies this importance. Variants such as SLCO1B1 c.521T>C reduce hepatic uptake of statins, elevating plasma concentrations and predisposing to statin-induced myopathy [25]. CPIC guidelines recommend dose adjustment or alternative statins in carriers of reduced-function alleles.

ATP-binding cassette (ABC) transporters, including ABCB1 (P-glycoprotein) and ABCG2 (breast cancer resistance protein), modulate drug absorption, distribution, and efflux at physiological barriers. Their polymorphisms influence oral bioavailability of chemotherapeutics, antivirals, and central nervous system drugs. For instance, ABCB1 variants alter response to antiepileptic drugs, while ABCG2 affects pharmacokinetics of tyrosine kinase inhibitors [26].

Non-CYP enzymes such as N-acetyltransferase 2 (NAT2) and aldehyde dehydrogenase 2 (ALDH2) also contribute to interindividual variability. NAT2 polymorphisms govern acetylation phenotypes, shaping isoniazid toxicity and therapeutic efficacy in tuberculosis treatment. Meanwhile, ALDH2 deficiency, common in East Asian populations, impairs aldehyde metabolism, predisposing to alcohol intolerance and influencing drug metabolism pathways [27].

Importantly, transporter pharmacogenomics extends to herb–drug interactions. Natural products such as St. John's Wort modulate transporter activity via pregnane X receptor induction,

complicating therapeutic predictability [28]. Thus, transporter and non-CYP pharmacogenomics expand the horizon of precision medicine beyond classic metabolic genes.



Figure 18.2: Role of Transporters in Pharmacogenomics

Diagram showing SLCO1B1 uptake in hepatocytes, ABC transporters mediating efflux at intestinal, hepatic, and blood–brain barriers, and clinical implications: statin myopathy, chemotherapy resistance, CNS drug penetration.

18.7 Precision Dosing Algorithms and Tools

Precision dosing represents the operational arm of pharmacogenomics, translating genetic insights into individualized regimens. Bayesian adaptive modeling has been widely adopted in oncology and infectious disease therapeutics, particularly for vancomycin and immunosuppressants, where narrow therapeutic windows necessitate careful titration [29]. Integration of pharmacogenomics with therapeutic drug monitoring (TDM) provides dynamic models that refine dosing over time.

Mobile applications and web-based platforms now support clinicians in real-time decision-making. For instance, genotype-guided dosing calculators for warfarin and thiopurines are increasingly embedded into electronic health record systems, delivering actionable recommendations at the point

of care [30]. Artificial intelligence enhances these tools by integrating genetic, clinical, and laboratory data, while blockchain-based systems are emerging to secure sensitive genomic information [31].

Ultimately, precision dosing algorithms shift the paradigm from static, population-based dosing toward adaptive, patient-specific regimens, bridging pharmacogenomic science with bedside practice.

Table 18.2: Emerging Precision Dosing Tools and Algorithms

Tool/Platform	Application	Integration
Warfarin Dosing Algorithms	*CYP2C9* and *VKORC1*-based models	EHR decision support
Thiopurine Dosing Apps	*TPMT* and *NUDT15* dose calculators	Mobile and clinical pharmacy services
Bayesian TDM Software	Oncology, infectious disease drugs	Laboratory integration
AI-Guided CDSS	Multi-omic precision dosing	Predictive analytics
Blockchain Data Platforms	Secure genomic data exchange	Patient–provider networks

18.8 Ethical, Legal, and Economic Challenges

Despite its promise, pharmacogenomics raises complex ethical and legal concerns. Genetic information, by its very nature, is deeply personal and potentially stigmatizing. Laws such as the Genetic Information Nondiscrimination Act (GINA) in the United States and the General Data Protection Regulation (GDPR) in Europe provide safeguards against misuse, yet gaps in protection remain [32].

Economic barriers are equally critical. The cost of pharmacogenomic testing, although decreasing, still limits widespread access, especially in low- and middle-income countries. Insurance reimbursement policies vary significantly, shaping test adoption. Health technology assessments indicate that pre-emptive pharmacogenomic testing can be cost-effective when implemented at a population level, but upfront investment and infrastructure pose challenges [33].

Equity is another pressing issue. Minority and underrepresented groups remain poorly characterized in genomic studies, raising concerns about misclassification of risk and widening health disparities [34]. Ethical implementation therefore requires global collaboration, regulatory harmonization, and equitable research representation.

18.9 Future of Pharmacogenomics

The trajectory of pharmacogenomics is rapidly expanding into multi-omic and therapeutic frontiers. Genome editing tools such as CRISPR-Cas9 hold the potential to directly correct deleterious pharmacogenetic variants, although ethical, technical, and safety considerations remain [35]. Epigenetic regulation adds another layer of variability, with DNA methylation and microRNAs emerging as biomarkers of drug response. These pharmacoepigenomic insights could complement traditional genotype data to enhance prediction accuracy [36].

Proteogenomics, integrating proteomic data with genetic profiles, promises to unravel post-transcriptional regulation of drug targets, while advances in quantum computing may revolutionize predictive modeling by enabling real-time simulation of complex pharmacogenomic interactions [37].

Looking forward, the convergence of genomics, epigenetics, proteomics, and digital health technologies will shape a holistic precision medicine landscape, where pharmacogenomics functions not in isolation but as part of a broader system of individualized healthcare.

CONCLUSION

Pharmacogenomics and precision dosing represent a paradigm shift in clinical pharmacology, transitioning therapeutic decision-making from population averages to individual genetic and molecular signatures. Advances in genomic sequencing, regulatory frameworks, and digital health integration have enabled actionable pharmacogenomic insights to enter routine practice. Key genes such as CYP2D6, CYP2C19, TPMT, and SLCO1B1 now guide therapy in cardiology, oncology, psychiatry, and beyond. Precision dosing algorithms, AI-driven tools, and companion diagnostics further operationalize this knowledge, bridging research with bedside practice.

However, significant challenges remain. Cost-effectiveness, equity of access, and data privacy are persistent barriers. Furthermore, underrepresentation of diverse populations threatens the generalizability of pharmacogenomic findings. Ethical frameworks and international harmonization will be essential to ensure that the benefits of pharmacogenomics are distributed fairly.

The future lies in the integration of multi-omics, pharmacoepigenomics, and next-generation computational models, with CRISPR and proteogenomics representing promising avenues. Ultimately, pharmacogenomics is not merely a tool for optimizing drug therapy but a transformative pathway toward a fully personalized, precise, and equitable healthcare system.

REFERENCES

1. Roden DM, McLeod HL, Relling MV, et al. Pharmacogenomics. Lancet. 2019;394(10197):521–532.
2. FDA. Table of Pharmacogenomic Biomarkers in Drug Labeling. 2024.
3. Popejoy AB, Fullerton SM. Genomics is failing on diversity. Nature. 2016;538(7624):161–164.
4. Gaedigk A, Sangkuhl K, Whirl-Carrillo M, et al. Prediction of CYP2D6 phenotype from genotype across world populations. Genet Med. 2017;19(1):69–76.
5. Crews KR, Gaedigk A, Dunnenberger HM, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for codeine therapy. Clin Pharmacol Ther. 2021;109(1):210–218.
6. Relling MV, Schwab M, Whirl-Carrillo M, et al. Clinical implementation of pharmacogenomics: TPMT and NUDT15. Lancet Oncol. 2019;20(9):e496–e506.
7. Chen P, Lin JJ, Lu CS, et al. Carbamazepine-induced toxic effects and HLA-B*1502 screening in Taiwan. N Engl J Med. 2011;364:1126–1133.
8. Ramsey LB, Johnson SG, Caudle KE, et al. The Clinical Pharmacogenetics Implementation Consortium guideline for SLCO1B1 and simvastatin-induced myopathy. Clin Pharmacol Ther. 2014;96(4):423–428.
9. CPIC. Clinical Pharmacogenetics Implementation Consortium Guidelines. 2024.
10. Dunnenberger HM, Crews KR, Hoffman JM, et al. Preemptive clinical pharmacogenetics implementation: The eMERGE-PGx project. Am J Hum Genet. 2019;104(1):65–77.
11. Luzum JA, Pakyz RE, Elsey AR, et al. The pharmacogenomics research network translational pharmacogenetics program. Clin Pharmacol Ther. 2017;102(4):502–510.
12. van der Wouden CH, Cambon-Thomsen A, Cecchin E, et al. Implementing pharmacogenomics in Europe: The U-PGx project. Pharmacogenomics. 2017;18(7):733–736.

13. Johnson JA, Cavallari LH. Warfarin pharmacogenetics. Trends Cardiovasc Med. 2015;25(1):33–41.
14. Mega JL, Simon T, Collet JP, et al. Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel. JAMA. 2010;304(16):1821–1830.
15. Hoskins JM, Goldberg RM, Qu P, et al. UGT1A1*28 genotype and irinotecan-induced neutropenia. J Natl Cancer Inst. 2007;99(17):1290–1295.
16. Wan JCM, Massie C, Garcia-Corbacho J, et al. Liquid biopsies come of age: Towards implementation of circulating tumour DNA. Nat Rev Cancer. 2017;17(4):223–238.
17. Hicks JK, Bishop JR, Sangkuhl K, et al. Clinical Pharmacogenetics Implementation Consortium guideline for CYP2D6 and CYP2C19 genotypes and SSRIs. Clin Pharmacol Ther. 2015;98(2):127–134.
18. Matic M, de Wildt SN, Tibboel D, et al. OPRM1 and CYP2D6 genotype and response to opioid therapy. Pharmacogenomics. 2019;20(2):89–98.
19. US FDA. In Vitro Companion Diagnostic Devices. Guidance for Industry. 2020.
20. FDA. Pharmacogenomic Biomarkers in Drug Labeling. 2024.
21. Choi SW, Mak TS, O'Reilly PF. Tutorial: A guide to performing polygenic risk score analyses. Nat Protoc. 2020;15(9):2759–2772.
22. Ji Y, Skierka JM, Blommel JH, et al. Preemptive pharmacogenomics: Panel testing and interpretation. Pharmacogenomics. 2016;17(2):123–134.
23. GenomeAsia 100K Consortium. The GenomeAsia 100K project enables genetic discoveries across Asia. Nature. 2019;576(7785):106–111.
24. Beam AL, Manrai AK, Ghassemi M. Challenges to the reproducibility of machine learning models in health care. JAMA. 2020;323(4):305–306.
25. Ramsey LB, Johnson SG, Caudle KE, et al. The Clinical Pharmacogenetics Implementation Consortium guideline for SLCO1B1 and simvastatin-induced myopathy. Clin Pharmacol Ther. 2014;96(4):423–428.
26. Bruhn O, Cascorbi I. Polymorphisms of the drug transporters ABCB1, ABCC1, ABCC2, and ABCG2 and their impact on drug therapy. Expert Opin Drug Metab Toxicol. 2014;10(3):307–333.
27. Sabbagh A, Darlu P, Crouau-Roy B, Poloni ES. Arylamine N-acetyltransferase 2 (NAT2) diversity and evolution in humans. Pharmacogenomics J. 2011;11(6):489–500.
28. Zhou S, Chan E, Pan SY, Huang M. Pharmacogenomics of herbal medicine–drug interactions. Curr Pharmacogenomics Person Med. 2012;10(1):16–29.
29. Neely M, van Guilder M, Yamada W, et al. Accurate detection of outliers and subpopulations with Pmetrics, a nonparametric and parametric pharmacometric modeling and simulation package for R. Ther Drug Monit. 2012;34(4):467–476.
30. Cavallari LH, Beitelshees AL, Blake KV, et al. Implementing genotype-guided antiplatelet therapy: The University of Florida Health Personalized Medicine Program. Am Heart J. 2014;167(1):17–24.
31. Ozdemir V, Dove ES, Gürsoy UK, et al. Personalized medicine beyond genomics: Understanding ecosystem innovation and ethical frameworks. OMICS. 2017;21(7):373–382.
32. Hudson KL, Holohan MK, Collins FS. Keeping pace with the times—the Genetic Information Nondiscrimination Act of 2008. N Engl J Med. 2008;358:2661–2663.
33. Phillips KA, Deverka PA, Hooker GW, Douglas MP. Genetic test availability and spending: Where are we now? Where are we going? Health Aff. 2018;37(5):710–716.

34. Bentley AR, Callier SL, Rotimi CN. Diversity and inclusion in genomic research: Why the uneven progress? J Community Genet. 2017;8(4):255–266.
35. Musunuru K, Cathomen T, Hirschi KK, et al. Genome editing and cardiovascular disease. Nat Rev Cardiol. 2017;14(1):11–20.
36. Sharma S, Kelly TK, Jones PA. Epigenetics in cancer. Carcinogenesis. 2010;31(1):27–36.
37. Borrelli R, Longhi G, Pizzi G, et al. Quantum computing in drug discovery: Advancing personalized medicine. Trends Pharmacol Sci. 2022;43(12):998–1010.